vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $200.5M, roughly 1.2× ROGERS CORP). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 2.2%, a 8.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 5.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $1.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -3.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
ANIP vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $200.5M |
| Net Profit | $27.5M | $4.5M |
| Gross Margin | — | 32.2% |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 2.2% |
| Revenue YoY | 29.6% | 5.2% |
| Net Profit YoY | 367.5% | 421.4% |
| EPS (diluted) | $1.14 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $247.1M | $201.5M | ||
| Q3 25 | $227.8M | $216.0M | ||
| Q2 25 | $211.4M | $202.8M | ||
| Q1 25 | $197.1M | $190.5M | ||
| Q4 24 | $190.6M | $192.2M | ||
| Q3 24 | $148.3M | $210.3M | ||
| Q2 24 | $138.0M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $27.5M | $4.6M | ||
| Q3 25 | $26.6M | $8.6M | ||
| Q2 25 | $8.5M | $-73.6M | ||
| Q1 25 | $15.7M | $-1.4M | ||
| Q4 24 | $-10.3M | $-500.0K | ||
| Q3 24 | $-24.2M | $10.7M | ||
| Q2 24 | $-2.3M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 3.5% | ||
| Q3 25 | 15.9% | 7.3% | ||
| Q2 25 | 6.6% | -33.3% | ||
| Q1 25 | 13.3% | -0.2% | ||
| Q4 24 | -2.3% | -6.6% | ||
| Q3 24 | -13.8% | 6.9% | ||
| Q2 24 | 3.7% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 11.1% | 2.3% | ||
| Q3 25 | 11.7% | 4.0% | ||
| Q2 25 | 4.0% | -36.3% | ||
| Q1 25 | 8.0% | -0.7% | ||
| Q4 24 | -5.4% | -0.3% | ||
| Q3 24 | -16.3% | 5.1% | ||
| Q2 24 | -1.7% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $1.14 | $0.20 | ||
| Q3 25 | $1.13 | $0.48 | ||
| Q2 25 | $0.36 | $-4.00 | ||
| Q1 25 | $0.69 | $-0.08 | ||
| Q4 24 | $-0.45 | $-0.04 | ||
| Q3 24 | $-1.27 | $0.58 | ||
| Q2 24 | $-0.14 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.2B |
| Total Assets | $1.4B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $285.6M | $197.0M | ||
| Q3 25 | $262.6M | $167.8M | ||
| Q2 25 | $217.8M | $157.2M | ||
| Q1 25 | $149.8M | $175.6M | ||
| Q4 24 | $144.9M | $159.8M | ||
| Q3 24 | $145.0M | $146.4M | ||
| Q2 24 | $240.1M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $540.7M | $1.2B | ||
| Q3 25 | $505.8M | $1.2B | ||
| Q2 25 | $436.8M | $1.2B | ||
| Q1 25 | $418.6M | $1.3B | ||
| Q4 24 | $403.7M | $1.3B | ||
| Q3 24 | $405.9M | $1.3B | ||
| Q2 24 | $455.8M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $5.8M |
| Free Cash FlowOCF − Capex | $29.1M | $1.1M |
| FCF MarginFCF / Revenue | 11.8% | 0.5% |
| Capex IntensityCapex / Revenue | 0.5% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $30.4M | $46.9M | ||
| Q3 25 | $44.1M | $28.9M | ||
| Q2 25 | $75.8M | $13.7M | ||
| Q1 25 | $35.0M | $11.7M | ||
| Q4 24 | $15.9M | $33.7M | ||
| Q3 24 | $12.5M | $42.4M | ||
| Q2 24 | $17.4M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $29.1M | $42.2M | ||
| Q3 25 | $38.0M | $21.2M | ||
| Q2 25 | $71.8M | $5.6M | ||
| Q1 25 | $32.5M | $2.1M | ||
| Q4 24 | $13.5M | $18.3M | ||
| Q3 24 | $7.7M | $25.2M | ||
| Q2 24 | $13.0M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 11.8% | 20.9% | ||
| Q3 25 | 16.7% | 9.8% | ||
| Q2 25 | 34.0% | 2.8% | ||
| Q1 25 | 16.5% | 1.1% | ||
| Q4 24 | 7.1% | 9.5% | ||
| Q3 24 | 5.2% | 12.0% | ||
| Q2 24 | 9.4% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.5% | 2.3% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 1.9% | 4.0% | ||
| Q1 25 | 1.3% | 5.0% | ||
| Q4 24 | 1.3% | 8.0% | ||
| Q3 24 | 3.2% | 8.2% | ||
| Q2 24 | 3.2% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.10× | 10.20× | ||
| Q3 25 | 1.66× | 3.36× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ROG
Segment breakdown not available.
